A small group of patients with an otherwise incurable form of T‑cell leukaemia have seen their cancer driven into remission by an innovative form of immune therapy.
The treatment uses T-cells – a type of white blood cell – from a healthy donor, re-engineered in the lab to recognise and attack leukaemia cells. Unlike personalised cancer therapies made from each patient’s own cells, these can be prepared in advance as an “off-the-shelf” product and given quickly to people in urgent need.
